A woman who lost 64 pounds on a compounded form of the weight loss drug semaglutide, marketed as Wegovy and Ozempic, started ...

Telehealth company Hims & Hers is playing offense in a new commercial slated to air during the Super Bowl next month. | Telehealth company Hims & Hers is playing offense in a new commercial slated to ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

Hims & Hers may leverage FDA compounding exemptions to further extend its compounded GLP-1 offerings. Learn why HIMS stock is ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists often partially inform or misinform consumers.

FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

"I'm so devastated that this option is going away," she says. For now, her doctor is going to switch her over to compounded semaglutide — the active pharmaceutical ingredient in Ozempic and Wegovy, ...

She was prescribed compound semaglutide, a cheaper, custom-made version of the active drug in Ozempic and Wegovy, in May 2022 and lost a staggering 64lbs in six months. But then she made a big ...

More than one-third of websites selling their own versions implied the products were the same as the FDA-approved drugs.

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform ...

Staci Rice lost 64 pounds on a compounded form of the weight loss drug semaglutide. It was expensive so she tried to maintain her weight loss without the medication, and gained 26 pounds.

Chetty, from the Yale University School of Medicine in New Haven, Connecticut, and colleagues examined advertising practices of websites selling compounded GLP-1 RAs, including semaglutide ...